Some stocks are one-hit wonders, making a big splash when they first appear, then quickly fizzling into obscurity or oblivion. But for other stocks, that initial big move is only a preview for even bigger and better gains to come.
Today, we've listed three stocks that made some of the biggest upward moves over the past month, despite the incredible volatility in the market, which we'll pair with the ratings issued by our Motley Fool CAPS community. The higher each stock's rating, the greater CAPS members' faith in that company's ability to keep on beating the market.
1 Month % Change
CAPS Rating (out of 5)
Source: FinViz.com; 1 Month % change from Dec. 9 to Jan. 11.
While you were out, the markets rebounded, but they may turn tail again if Europe's fragile financial system falls apart. So before we get shaken out again, let's see why the CAPS community thinks some of these companies might continue to outperform the market.
A mighty temblor
Better-than-expected sales of prostate cancer drug Provenge helped lift Dendreon out of the doldrums and start the new year off right. Revenues came in at $82 million, up 25% sequentially, though growth rates were off from the 30% seen in the previous period.
Dendreon had to change its tune about the drug's growth prospects after initially promising $350 million to $400 million in sales. Instead, they came in at $228 million and management was warning that second-half growth of Provenge would only be "modest." That's why, when it reported the numbers it did, the stock took off.
Modesty is not Dendreon's only problem, as prostate cancer drugs from competitors like Medivation
Almost 84% of the CAPS members rating Dendreon believe it will still be able to carve out a niche for itself, but tell us on the Dendreon CAPS page or in the comments section below if you think it will ever gain altitude again, then add the biotech to your watchlist to see if it crashes and burns.
Medical device maker Delcath Systems initially got a boost from appointing a distinguished doctor to its medical advisory board, then followed it up with an announcement that it had signed an agreement with an equally prestigious European cancer research center.
Delcath is trying to get its minimally invasive chemosaturation technology approved. The Chemosat delivery system delivers significantly higher doses of drugs to the organ, in this case the liver, without risking exposure to the whole body. Others are focusing on liver cancer, too, but Bristol-Myers Squibb
CAPS member siri22 believes that despite the setbacks Delcath has received at the hands of the FDA, it will be a big winner for his portfolio in the future: "Dollar-cost average in, buying as much as I can, medical device for specific chemo infusion, 10 bagger check back in 2 years."
Shake, rattle, and roll
These two stocks shook the market this past month, but the Fool has found one company that's digging up massive profits and is likely to continue to do so if the markets become rattled. Roll on over to get your free copy, but hurry, because it's available only for a limited time.
Fool contributor Rich Duprey holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Apple, Inc.'s HomePod Launch Could Be Imminent
Contract manufacturer Inventec has reportedly started shipping the Mac maker's first smart speaker.
Why Aerohive Networks Inc. Stock Plunged Today
Sales execution issues hurt the enterprise mobility leader's top line toward the end of the year. Here's what investors need to know.
How Kohl's Corporation Sharpened Its Retail Edge
Pragmatic programs over the last two years have undergirded the recent rise of Kohl's shares.